BofA analyst Alec Stranahan downgraded Day One Biopharmaceuticals to Underperform from Buy with a $9 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DAWN:
- Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress
- JPMorgan SMid cap biotech analyst to hold analyst/industry conference call
- Day One Biopharmaceuticals price target lowered to $44 from $48 at Needham
- Oppenheimer still not a buyer of Day One Biopharmaceuticals despite selloff
- Day One not changing endpoint for FIREFLY-1 trial, says JonesResearch